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ASPP = apoptosis stimulating protein of p53; A-T = ataxia-telangectasia; ATM = ataxia-telangectasia mutated; ATR = ataxia-telangectasia and
Rad3-related protein; Chk2 = human homologue of Rad53; DCIS = ductal carcinoma in situ; LOH = loss of heterozygosity; maspin = mammary
serine protease inhibitor; MDM2 = mouse double minute 2; p14ARF = alternative product of the INK4 gene; σ = 14-3-3sigma.
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Introduction
First described in 1979, and initially believed to be an onco-
gene, p53 was the first tumour suppressor gene to be iden-
tified. p53 functions to eliminate and inhibit the proliferation
of abnormal cells, thereby preventing neoplastic develop-
ment. Abrogation of the negative growth regulatory func-
tions of p53 occurs in many, perhaps all, human tumours.
The p53 signalling pathway is in ‘standby’ mode under
normal cellular conditions. Activation occurs in response to
cellular stresses, and several independent pathways of p53
activation have been identified that appear to be dependent
on distinct upstream regulatory kinases [1] (Fig. 1). These
include an ataxia-telangectasia mutated (ATM)/human
homologue of Rad53 (Chk2)-dependent pathway activated
by DNA double-strand breaks, a second pathway depen-
dent on the alternative product of the INK4 gene, p14ARF
(which is activated by expression of oncogenes), and a third
pathway whose activity is increased by cytotoxic anti-tumour
agents and ultraviolet light, but is independent of ATM,
Chk2 and p14ARF. Activation of this pathway may be medi-
ated by other kinases such as the ATM relative ataxia-
telangectasia and Rad3-related protein (ATR) [1].
Activation results in an increase in the levels of p53
protein due to reduced mouse double minute 2 (MDM2)-
dependent proteolytic degradation, and increased affinity
of p53 for DNA. Whereas phosphorylation of the N-termi-
nus may affect the stability of p53, lysine acetylation
and/or serine phosphorylation in the C-terminus of the
protein promotes DNA binding. As a result of activation,
the wild-type protein acquires sequence-specific DNA
binding activity, and an increasing number of genes are
being identified as transcriptional targets of wild-type p53
[2]. These can be placed into a number of classes accord-
ing to their functions.
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p53 mutation remains the most common genetic change identified in human neoplasia. In breast
cancer, p53 mutation is associated with more aggressive disease and worse overall survival. The
frequency of mutation in p53 is, however, lower in breast cancer than in other solid tumours. Changes,
both genetic and epigenetic, have been identified in regulators of p53 activity and in some downstream
transcriptional targets of p53 in breast cancers that express wild-type p53. Molecular pathological
analysis of the structure and expression of constituents of the p53 pathway is likely to have value in
diagnosis, in prognostic assessment and, ultimately, in treatment of breast cancer.
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Inhibitors of cell cycle
These targets include the cyclin-dependent kinase inhibitor
p21Waf1, 14-3-3sigma (σ), which tethers cyclin B1–CDK1
complexes in the cytoplasm, contributing to maintenance of
G2 cell cycle arrest, and GADD45 and BTG.
Apoptosis regulators
Proapoptotic proteins directly induced by p53 include,
among others, Bax, Apaf 1, PUMA, p53AIP1, PIDD and
NOXA.
DNA repair
Wild-type p53 directly activates a number of genes that
function in pathways of DNA repair, including a ribonu-
cleotide reductase gene, p53R2, involved in repair of DNA
damage.
Inhibitors of angiogenesis and metastasis
Perhaps the most interesting member of this class of p53-
inducible genes is mammary serine protease inhibitor
(maspin), a serine protease inhibitor that inhibits angiogen-
esis, invasion and metastasis. A second recognised
metastasis suppressor protein, KAI1, has also been
reported to be regulated by p53.
p53 is inactivated by multiple mechanisms in
cancer
p53 remains the most commonly mutated gene in many
common human cancers, with mutations (principally, but not
exclusively, missense) estimated to occur in 50% of all
cancers. Mutant proteins are almost always defective for
sequence-specific DNA binding, and thus for transactivation
of genes upregulated by the wild-type protein [3]. Interest-
ingly, the proportion of missense mutations in p53 is higher
than that seen in other tumour suppressor genes, suggest-
ing that expression of p53 mutants may confer selective
advantage over and above loss of wild-type function [4].
Consistent with this hypothesis, many human tumour-
associated p53 mutants possess a number of properties
absent from the wild-type protein [3]. In a high proportion
of cancers lacking mutations, p53 function is compro-
mised by other recognised mechanisms [1]. In virus-
associated cancers, this may occur via interaction with
virally encoded proteins resulting in sequestration or
enhanced degradation of p53. MDM2 binds to p53 and
promotes the ubiquitination of the C-terminus of p53 and
subsequent degradation. p14ARF interacts with MDM2,
preventing association of p53 and MDM2, and thereby
Figure 1
A simplified model of some of the components of p53 signalling. Under normal conditions, the p53 pathway operates on ‘standby’ mode. Activation
occurs in response to a variety of cellular stresses such as DNA damage and expression of activated oncogenes. See [1] for a more detailed
description of the pathways activated by specific stresses. Post-translational modifications (such as phosphorylation at the indicated serine
residues) activate the protein for DNA binding and transactivation of downstream ‘effector’ genes that mediate the tumour suppressor actions of
p53. The outcome of activation depends on the nature and magnitude of the stress, its transduction via specific upstream kinases, and the
resultant programme of p53-dependent gene expression. Transcriptional coactivators such as apoptosis stimulating protein of p53 and BRCA1
(not shown) may further ‘fine tune’ the response and, in some cases, preferentially promote specific cellular responses such as apoptosis. Many of
the components of this signalling pathway are targets for genetic and/or epigenetic changes in breast cancer as described in the text. Not shown
is the induction of MDM2, which acts as a negative feedback regulator of the pathway by promoting the degradation of p53. Because of space
limitations, other important constituents of the pathway have had to be omitted.Breast Cancer Research    Vol 4 No 2 Gasco et al.
stabilising p53. Degradation of p53 may therefore be inap-
propriately stimulated by overexpression of MDM2 or by
deletion or epigenetic silencing of p14ARF. Loss of this
protein has been reported in several common human
cancers, particularly (but not exclusively) those in which
the p53 gene is wild-type. Yet another mechanism of in-
activation involves cytoplasmic sequestration of p53
protein, preventing nuclear localisation of the protein and
thus inhibiting its activity.
Mechanisms of inactivation of p53 in breast
cancer
p53 mutation in breast cancer
Germ-line mutations in p53 occur in a high proportion of
individuals with the Li–Fraumeni cancer susceptibility syn-
drome, which confers an increased risk of breast cancer
[5]. This implies an important role for p53 inactivation in
mammary carcinogenesis, and the structure and expres-
sion of p53 has been widely studied in breast cancer. In
early studies, expression of mutant p53 was demonstrated
in breast cancer cell lines [6]. Loss of heterozygosity
(LOH) in the p53 gene was shown to be a common event
in primary breast carcinomas [7] and this is accompanied
by mutation of the residual allele in some cases. In colon
carcinomas the residual p53 allele is mutant in the vast
majority of cases, but in breast cancer at least 60% of
cases with LOH retain a wild-type p53 allele [7].
Nevertheless, numerous studies have identified coding
mutations in p53 in breast cancer and this is now recog-
nised as a common, but by no means ubiquitous, somatic
genetic change in breast cancer. Indeed, a comprehensive
meta-analysis revealed that only approximately 20% of all
cases express mutant p53 [8]. Several studies have
sought to identify the stage of breast tumourigenesis at
which p53 mutation occurs. Careful studies of micro-
dissected tumour material show that low-grade ductal
carcinoma  in situ (DCIS) is essentially devoid of
mutations, whereas mutations are more common in high-
grade DCIS [9].
Although the overall frequency of p53 mutation in breast
cancer is approximately 20% [8], certain types of the
disease are associated with higher frequencies. For
example, a number of studies have identified an
increased rate of p53 mutations in cancers arising in car-
riers of germ-line BRCA1 and BRCA2 mutations
[10,11]. Moreover, a distinct spectrum of p53 mutations
occurs in such carcinomas [12]. Strikingly, in typical
medullary breast carcinomas, p53 mutation occurs in
100% of cases [13]. This is of particular interest, since it
is now well recognised that medullary breast cancers
share clinicopathological similarities with BRCA1-associ-
ated cases. Indeed, methylation-dependent silencing of
BRCA1 expression occurs commonly in medullary breast
cancers [14].
The p53 pathway in breast cancers lacking p53 mutations
Although the structure of p53 has been extensively
studied, the absolute frequency of mutations in breast
cancer is significantly lower than that in many other
common cancers. What are the molecular mechanisms by
which cancers lacking mutations subvert the tumour sup-
pressor properties of wild-type p53? Studies of this ques-
tion have shed fascinating light into some of the myriad
regulatory pathways of p53 function.
An early insight into mechanisms of p53 inactivation in
breast cancer was afforded by a study of breast cancers
of varying p53 mutation status. It was shown that, in a pro-
portion of cases with wild-type p53, there was only cyto-
plasmic protein staining [15]. Exclusion of the wild-type
protein from the nucleus thus represents a potential mech-
anism for p53 inactivation independent of mutation. Sub-
sequently, alterations have been identified both in
upstream regulatory proteins and in downstream p53-
induced proteins that may disable or compromise the
pathway in breast cancers lacking mutations.
Changes in upstream regulators of p53
Aside from the two well-recognised breast cancer suscep-
tibility genes BRCA1 and BRCA2, it is an attractive
hypothesis that mutations in other genes with lower pene-
trance may account for a significant proportion of heredi-
tary breast cancers. One such gene may be ATM, the
gene mutated in ataxia-telangectasia (A-T). The link
between ATM and p53 was suggested in early studies
revealing defective induction of p53 following irradiation of
A-T cells. It has subsequently been established that phos-
phorylation of both p53 and BRCA1 in response to γ-irra-
diation occurs via ATM.
A-T patients have a high incidence of cancer, and some
develop breast carcinomas [16]. A recent study examined
the entire ATM coding sequence in a large series of breast
cancer patients and identified heterozygosity for truncat-
ing mutations in approximately one in 50 patients, consis-
tent with the hypothesis that A-T heterozygotes are more
common in breast cancer patients than in the general pop-
ulation [17]. It has been hypothesised that inactivation of
ATM may be an alternative to p53 mutation in leukaemia.
There is evidence that low or absent expression of ATM
occurs commonly in sporadic breast cancer [18]. Interest-
ingly, some cancers in this study had both low ATM
expression and p53 mutation, suggesting that the inactiva-
tion of the two genes is not necessarily exclusive.
A second protein operating upstream to transduce DNA
damage to phosphorylation of p53 is Chk2. Chk2 is acti-
vated (by phosphorylation of threonine 68) by ATM in
response to double strand breaks and, in turn, catalyses
phosphorylation of p53 at serine 20. Analysis of Chk2
sequence in Li–Fraumeni families lacking p53 mutationsAvailable online http://breast-cancer-research.com/content/4/2/070
identified heterozygous germ-line mutations in some cases
[19], suggesting that Chk2 is a human tumour suppressor
gene and implying that loss of function in Chk2 might be
equivalent to p53 mutation. Several studies have subse-
quently examined Chk2 germ-line sequence in families
with hereditary breast cancer. In all cases, germ-line muta-
tions in Chk2 were uncommon [20,21]. Chk2 mutations in
sporadic breast cancers are also rare, but a significant
proportion of such cases exhibit reduced or absent
expression of Chk2 [22]. Interestingly, cases with loss of
Chk2 expression were both wild-type and mutant for p53.
The steady-state level of p53 mRNA is lower in many
breast cancers than in normal breast epithelium [23].
Detailed analysis of the p53 promoter has revealed the
presence of several consensus-binding sites for the
homeobox protein HoxA5, and these are responsive to
HoxA5. In a high proportion of primary breast carcinomas,
expression of HoxA5 is significantly reduced. This is attrib-
utable to aberrant methylation of the Hox A5 promoter
[23]. By limiting basal expression of p53 mRNA, epige-
netic silencing of HoxA5 thus represents a novel and
important mechanism by which p53 signalling is attenu-
ated in breast cancer. It will be of interest to determine
whether expression of other components of the pathway is
also subject to similar regulation.
Changes in p53 transcriptional target genes
Perhaps surprisingly, relatively few studies have investigated
the status of these genes in human cancer in general, and in
breast cancer specifically. One such gene of particular inter-
est is σ, which was originally identified in squamous epithe-
lium and shown to be downregulated in a small number of
breast cancer cell lines. It was subsequently shown that σ is
a direct transcriptional target for p53 and that it mediates
maintenance of a G2 checkpoint. Analysis in primary breast
carcinomas revealed that, despite the absence of intragenic
mutation and LOH, σ is subject to methylation-dependent
silencing in a very high proportion of cases [24]. Moreover,
loss of expression is present in a significant number of
cases of DCIS [25]. It will be interesting to determine
whether any relationship exists between p53 status and
silencing of σ in breast cancer.
A second key gene whose expression is directly upregu-
lated by wild-type p53 is MDM2. Amplification and over-
expression of MDM2 is a recognised mechanism of p53
inactivation, but although one study detected MDM2
amplification in a small proportion of cases [26], amplifica-
tion of MDM2 is an infrequent event in breast cancer [27].
A second mechanism to promote MDM2-dependent p53
degradation involves loss of p14ARF either by mutation,
deletion or epigenetic silencing. Mutations and deletions
in p14ARF are uncommon in breast cancer, but absent or
reduced expression occurs in a subset of cases and this is
associated with aberrant hypermethylation of the p14ARF
promoter [28]. Inactivation is frequently seen in cases with
p53 mutation, implying that loss of p14ARF expression is
not functionally equivalent to mutation of p53. Neverthe-
less, these results suggest a role for p14ARF inactivation in
breast cancer.
p21Waf1 (also known as Cip1) is an inhibitor of the cyclin-
dependent kinases and is directly induced by p53. The
Waf1 gene is not a frequent target for mutational inactiva-
tion in breast (or other) cancers [29]. Moreover, p21Waf1
expression is not significantly associated with clinical
outcome in breast cancer [30].
One of the most commonly deleted chromosomal regions
in breast cancer is 11q23-q25, which contains a number
of putative tumour suppressor loci, including ATM, CHK1,
PPP2R1B and PIG8. A recent study of the structure of
these genes in early onset breast cancer determined that
the gene most frequently mutated in this region was PIG8,
a gene induced by p53 and a putative mediator of p53-
dependent apoptosis [31]. Loss of PIG8 function via inac-
tivating mutations thus represents a further potential
mechanism by which p53-dependent apoptosis can be
impaired in breast cancer.
Changes in p53 coactivators
In addition to proteins such as ATM, ATR and Chk2 that
regulate the stability and function of p53 through phos-
phorylation, a second, functionally distinct, group of pro-
teins is now emerging that appear to operate as cofactors
stimulating one or more of the wild-type properties of p53.
One such family with possible involvement in breast
cancer is the apoptosis stimulating protein of p53 (ASPP).
Two members of this family (ASPP1 and ASPP2),
encoded by separate genes, have recently been
described [32].
Expression of either ASPP1 or ASPP2 stimulates the pro-
apoptotic function of wild-type p53 by increasing p53-
dependent induction of apoptotic effectors such as Bax
and PIG3, whereas expression of nonapoptotic proteins
such as p21Waf1 was much less affected. In primary breast
cancers lacking p53 mutation, expression of both ASPP1
and ASPP2 was reduced. These observations are sup-
ported by an earlier report that, using microarray method-
ology, also identified p53 BP2 (ASPP2) downregulation in
breast cancer [33]. Taken together, these studies suggest
that downregulation of ASPP proteins attenuates p53-
dependent apoptosis, thus conferring a selective advan-
tage to breast carcinomas with intact p53.
Another transcriptional coactivator for p53 is BRCA1. It is,
of course, well known that germ-line mutations in BRCA1
predispose carriers to breast and ovarian cancer. BRCA1
is phosphorylated after DNA damage by ATM, ATR and
Chk2. BRCA1 associates with the C-terminus of wild-typep53 and stimulates transcription from p53-responsive pro-
moters, whereas tumour-associated mutants of BRCA1
are deficient in coactivating activity [34]. Although somatic
mutations in BRCA1 have not been described in sporadic
breast cancer, expression of BRCA1 is decreased in the
majority of cases, implying a further mechanism whereby
p53 function can be inhibited in breast carcinomas. Down-
regulation of BRCA1 expression is attributable to methyla-
tion-dependent silencing in a small proportion of cases
[35], but the mechanism underlying the low level of
expression seen in many sporadic breast cancers awaits
clarification.
The DNA binding and therefore the transcriptional activat-
ing function of p53 is potentiated by acetylation of lysine
residues in the C-terminus of the protein. This is accom-
plished by the histone acetyltransferase p300. Truncating
mutations in p300 have been described in breast cancer
cell lines and primary breast cancer, and a missense muta-
tion in a further breast cancer cell line [36]. In some cases,
mutations in p300 and p53 are not mutually exclusive,
suggesting that mutation of p300 does not abrogate
selective pressure for p53 mutation.
p53 status may be predictive of outcome in
breast cancer
The association between p53 alterations and clinical
outcome in breast cancer has been the subject of numer-
ous investigations. The possibility that p53 status influ-
ences biological behaviour was raised in an early study in
which the presence of p53 mutations in aggressive breast
cancer was demonstrated [37], and the majority of studies
support an association between worse survival and the
presence of p53 mutations. This association was con-
firmed in a comprehensive meta-analysis of the effect of
somatic p53 mutations on prognosis in breast cancer [8].
Potential correlations between the type of p53 mutation
and the clinical phenotype in breast cancer have been
described [38]. In this study, it was shown that mutations
affecting amino acids critical for DNA binding were asso-
ciated with very aggressive cancers, whereas null muta-
tions and other missense mutations were associated with
an indeterminate clinical phenotype. A recent study sug-
gests that p53 mutation may be an important molecular
genetic correlate of breast cancer progression [39]. In a
further study of primary breast carcinomas, expression of
the angiogenic vascular endothelial growth factor was
shown to correlate with poor prognosis and with mutation
in p53 [40].
The serpin family member maspin is an inhibitor of angio-
genesis, invasion and metastasis. A step-wise decrease in
the expression of maspin in the sequence DCIS > invasive
cancer > lymph node metastasis has been described,
strongly supporting an important role in breast cancer pro-
gression [41]. Maspin is directly transcriptionally induced
by wild-type p53, thus providing an interesting connection
between p53 and progression in ductal breast carcinomas
[42]. It will clearly be of interest to determine how expres-
sion of maspin relates to p53 status in breast cancer.
Studies of the effect of p53 mutations on chemosensitivity
of human tumours have produced conflicting results. In
breast cancer, there is evidence that specific mutations
correlate with primary resistance to doxorubicin and that
the presence of such mutations may be predictive of early
relapse [43]. This hypothesis was further supported by a
later study from the same group [44]. In another study,
cancers with p53 mutation were more likely to respond to
paclitaxel [45].
A number of recent reports have described the detection
of tumour-specific DNA in plasma from patients with
breast carcinomas. p53 mutations can be detected in
peripheral blood in a significant proportion of patients
whose primary tumours contain mutations. Furthermore,
the presence of p53 mutations in plasma DNA is strongly
correlated with various clinicopathological parameters and
is a significant prognostic factor [46]. p53 autoantibodies
are also detectable in patients with breast cancer. These
were reported to occur in 15% of patients but the pres-
ence of such antibodies had no relationship to disease
status [47].
p53 family members in breast cancer
Two structural and partial functional homologues of p53
(p63 and p73) have been described. Mutations in p73 are
uncommon in human neoplasia, overexpression of p73
being the most frequent abnormality of p73. A subset of
cases in breast cancer overexpress p73, and in one study
this was associated with lymph node metastasis, vascular
invasion and high-grade malignancy [48]. Analysis of p63
in breast tissue revealed that expression, specifically of the
transdominant DNp63, is restricted exclusively to myoep-
ithelial cells. Indeed, p63 has been proposed as a specific
and sensitive marker for myoepithelial cells [49].
Conclusions
Abundant data from mechanistic, molecular pathological
and transgenic animal studies support an important role
for p53 in mammary carcinogenesis. However, despite the
convincing evidence implicating loss of function of p53 in
breast neoplasia, mutations in the gene occur at a signifi-
cantly lower frequency than in other common solid
tumours. Over the past few years, knowledge of the
upstream pathways regulating p53 activity has increased
greatly and numerous transcriptional targets for p53 have
been described. These discoveries have allowed analysis
of the molecular mechanisms, in addition to mutation, by
which p53 is disabled in breast cancer and have provided
new insights into pathways of neoplasia in the breast. Mol-
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ecular pathological analysis of specific components of the
p53 pathway is likely to have diagnostic and prognostic
utility in breast cancer. Moreover, a number of innovative
strategies have been proposed to restore p53 function to
tumours [50]. It will be of great interest to observe how
these and other novel therapeutic approaches targeted to
the p53 pathway impact on clinical outcome in breast
cancer.
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